Eubel Brady Suttman Asset Management Inc Lowers stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Eubel Brady Suttman Asset Management Inc reduced its stake in Johnson & Johnson by 1.77% during the most recent quarter end. The investment management company now holds a total of 138,794 shares of Johnson & Johnson which is valued at $17,102,197 after selling 2,497 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Johnson & Johnson makes up approximately 5.79% of Eubel Brady Suttman Asset Management Inc’s portfolio.

Other Hedge Funds, Including , Jw Asset Management added JNJ to its portfolio by purchasing 6,000 company shares during the most recent quarter which is valued at $739,320. Johnson & Johnson makes up approx 0.52% of Jw Asset Management’s portfolio.Hutner Daniel Ellsworth boosted its stake in JNJ in the latest quarter, The investment management firm added 60 additional shares and now holds a total of 60,172 shares of Johnson & Johnson which is valued at $7,414,394. Johnson & Johnson makes up approx 6.25% of Hutner Daniel Ellsworth’s portfolio.Cadence Bank Na boosted its stake in JNJ in the latest quarter, The investment management firm added 1,041 additional shares and now holds a total of 62,224 shares of Johnson & Johnson which is valued at $7,730,710. Johnson & Johnson makes up approx 3.78% of Cadence Bank Na’s portfolio.Buckingham Asset Management reduced its stake in JNJ by selling 1,307 shares or 5.34% in the most recent quarter. The Hedge Fund company now holds 23,146 shares of JNJ which is valued at $2,867,789. Johnson & Johnson makes up approx 0.95% of Buckingham Asset Management’s portfolio.Johnston Asset Management reduced its stake in JNJ by selling 9,910 shares or 4.5% in the most recent quarter. The Hedge Fund company now holds 210,532 shares of JNJ which is valued at $26,268,078. Johnson & Johnson makes up approx 1.26% of Johnston Asset Management’s portfolio.

Johnson & Johnson opened for trading at $119.3 and hit $120.13 on the upside on Monday, eventually ending the session at $119.92, with a gain of 0.74% or 0.88 points. The heightened volatility saw the trading volume jump to 50,74,924 shares. Company has a market cap of $328,086 M.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *